

Remarks

The replacement sequence listing submitted herewith has been amended to include SEQ ID NOS: 11, 12, 13, 14 and 15. The replacement sequence listing has also been amended to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) outlined in the conference call with the Examiner on August 18, 2008. In the August 18, 2008 conference call with the Examiner, it was determined that the sequences represented in claims 1, 5 and 7 required a sequence listing identifier. All of the remaining information in the replacement sequence listing is identical to the information found in the sequence listing filed on May 20, 2005, in the above-captioned patent application.

In accordance with 37 C.F.R. § 1.825(a), the amendment to the paper copy of the sequence listing is made by the submission herewith of substitute sheets of the sequence listing. Support for the sequence information set forth in the paper copy of the sequence listing can be found throughout the specification as originally filed. The substitute sheets of the paper copy of the sequence listing therefore do not include any new matter.

In accordance with 37 C.F.R. § 1.825(b), the amendment to the paper copy of the sequence listing is accompanied by a substitute copy of the computer readable form (§ 1.821(e)) including all previously submitted data with the amendment incorporated therein. The substitute copy of the computer readable form of the sequence listing is the same as the substitute paper copy of the sequence listing submitted herewith.

Amendments to the Specification

The specification has been amended to include the appropriate sequence identifiers in accordance with 37 C.F.R. § 1.821(d). SEQ ID NOS: 11, 12, 13, 14 and 15 are supported, for example, at page 10, line 6 to page 11, line 13; page 12, lines 1-23; and page 13, lines 1-17. No new matter had been added by way of these amendments.

Amendments to the Claims

Upon entry of the foregoing amendments, claims 1, 2, 4, 5 and 7-15 are pending in the application, with claims 1, 5, 8, 9 and 10 being the independent claims. Claims 5 and 7-10 have been withdrawn by the Examiner. Claims 1, 4, withdrawn claim 5, withdrawn claim 7, withdrawn claim 8, withdrawn claim 9, withdrawn claim 10 and claim 11 have been amended. New claims 12-15 have been added.

The amendments to claims 1, 4, withdrawn claim 5, withdrawn claim 7, withdrawn claim 8, withdrawn claim 9, withdrawn claim 10 and claim 11 were proposed by the Examiner. Applicants have added sequence identifiers to claims 1, 5, 7, 8, 9 and 10. These amendments are supported by the Substitute Sequence Listing and the amendments to the specification submitted herewith. Applicants have cancelled claims 3 and 6 in accordance with the Examiner's Amendment. Applicants have added claims 12-15 to separate original claim 11 into separate dependent claims based on the chemical formula. Support for new claims 12-15 is found in original claim 11.


Applicants respectfully submit that these amendments place the application in condition for allowance and do not raise any new issue requiring further search or examination. These changes are believed to introduce no new matter, and their entry is respectfully requested.

Conclusion

Prompt and favorable consideration of this Amendment is respectfully requested. Applicants believe the present application is in condition for immediate examination. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


William B. Coblenz
Attorney for Applicants
Registration No. 57,104

Date: August 22, 2008

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

862489_1.DOC